{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T09:18:20Z","timestamp":1787649500130,"version":"build-2736575974"},"reference-count":35,"publisher":"MDPI AG","issue":"17","license":[{"start":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T00:00:00Z","timestamp":1787529600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Clin. Med.","JCM"],"abstract":"<jats:p>Background\/Objectives: To assess the acceptance of, attitudes towards, and concerns regarding allogeneic serum eye drops (Allo-SEDs) among patients treated with autologous serum eye drops (ASEDs). Methods: We conducted this investigator-initiated, cross-sectional, single-center survey at the Department of Ophthalmology, University Hospital Zurich, Switzerland. We consecutively recruited all patients using ASEDs during routine visits, who anonymously completed a 9-item questionnaire comprising eight 11-point Likert-scale items and one open numerical item on the daily application frequency. We assessed perceived ASED effectiveness, willingness to switch to Allo-SEDs under different scenarios, and concerns regarding safety, efficacy, and immunological risks. Results: Of 202 eligible patients, 107 returned the questionnaire (53.0%). The full eligible cohort had a median (IQR) age of 63.5 (49.2\u201375.0) years and a median ASED treatment duration of 4.0 (1.0\u20138.0) years. They rated ASEDs as highly effective (median 9, IQR 8.2\u201310.0) and applied them a median of 7 (5\u201310.5) times daily. Willingness to switch was low without clinical need (median 3, IQR 0\u20136; p = 1.0), increased when autologous production was no longer feasible (median 7, IQR 5\u20139; p &lt; 0.001), and was intermediate for general openness (median 5, IQR 2\u20138; p = 0.7). Concerns regarding infectious disease transmission, immunological reactions, and therapeutic efficacy correlated with lower willingness to switch (all r = \u22120.29 to \u22120.46). Daily application frequency did not correlate with acceptance. Conclusions: Patients were highly satisfied with ASEDs but were reluctant to switch to Allo-SEDs unless autologous production was no longer feasible. Among the domains assessed, concerns regarding infection, immunological reactions, and efficacy were the main barriers to acceptance, supporting targeted patient education.<\/jats:p>","DOI":"10.3390\/jcm15176537","type":"journal-article","created":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T14:49:34Z","timestamp":1787582974000},"page":"6537","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Acceptance of Allogeneic Serum Eye Drops Among Users of Autologous Serum Eye Drops\u2014A Survey-Based Study"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-9807-9623","authenticated-orcid":false,"given":"Frank","family":"Blaser","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, University Hospital Zurich, University of Zurich, 8091 Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammadjavad","family":"Abbasi","sequence":"additional","affiliation":[{"name":"School of Medicine and Surgery, University of Naples Federico II, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7152-2613","authenticated-orcid":false,"given":"Mario D.","family":"Toro","sequence":"additional","affiliation":[{"name":"Public Health Department, University of Naples Federico II, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy","family":"Hamann","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, University Hospital Zurich, University of Zurich, 8091 Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5431-4991","authenticated-orcid":false,"given":"Daniel","family":"Barthelmes","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, University Hospital Zurich, University of Zurich, 8091 Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7431-1774","authenticated-orcid":false,"given":"Sandrine A.","family":"Zweifel","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, University Hospital Zurich, University of Zurich, 8091 Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-7763-4665","authenticated-orcid":false,"given":"Martina M.","family":"Bosch","sequence":"additional","affiliation":[{"name":"Augenklinik Wettingen, 5430 Wettingen, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Meneau","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, University Hospital Zurich, University of Zurich, 8091 Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jana","family":"Schneider","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, University Hospital Zurich, University of Zurich, 8091 Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sadiq","family":"Said","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, University Hospital Zurich, University of Zurich, 8091 Zurich, Switzerland"},{"name":"Augenklinik Wettingen, 5430 Wettingen, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-1437-5102","authenticated-orcid":false,"given":"Vinoth","family":"Yogarasa","sequence":"additional","affiliation":[{"name":"Augenklinik Wettingen, 5430 Wettingen, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,8,24]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1001\/jamaophthalmol.2022.4394","article-title":"Prevalence and incidence of dry eye and meibomian gland dysfunction in the United States: A systematic review and meta-analysis","volume":"140","author":"McCann","year":"2022","journal-title":"JAMA Ophthalmol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.jtos.2017.05.003","article-title":"TFOS DEWS II epidemiology report","volume":"15","author":"Stapleton","year":"2017","journal-title":"Ocul. Surf."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"e067007","DOI":"10.1136\/bmjopen-2022-067007","article-title":"Patient-reported burden and overall impact of dry eye disease across eight European countries: A cross-sectional web-based survey","volume":"13","author":"Boboridis","year":"2023","journal-title":"BMJ Open"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"159","DOI":"10.4103\/joco.joco_46_24","article-title":"Epidemiological characteristics of dry eye disease in Asian and Asian female populations: A database-driven descriptive study","volume":"36","author":"Zhang","year":"2024","journal-title":"J. Curr. Ophthalmol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"3179","DOI":"10.1038\/s41433-021-01526-w","article-title":"Reducing the burden of ocular surface disease with serum eye drops","volume":"35","author":"Hossain","year":"2021","journal-title":"Eye"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Gemelli, C.N., Mondy, P., Kakkos, A., O\u2019Donovan, J., Diaz, P., Knight, E., and Hirani, R. (2023). Patient-reported outcomes of serum eye drops manufactured from Australian blood donations and packaged using Meise vials. Front. Med., 10.","DOI":"10.3389\/fmed.2023.1252688"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1111\/aos.12386","article-title":"Ready-made allogeneic ABO-specific serum eye drops: Production from regular male blood donors, clinical routine, safety and efficacy","volume":"92","author":"Nielsen","year":"2014","journal-title":"Acta Ophthalmol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"3036","DOI":"10.1111\/trf.12727","article-title":"Screening for HLA antibodies in plateletpheresis donors with a history of transfusion or pregnancy","volume":"54","author":"Baeten","year":"2014","journal-title":"Transfusion"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1111\/tme.13068","article-title":"Allogenic and autologous nondiluted serum eye drops\u2014Validation strategy compliant with good manufacturing practice","volume":"34","author":"Dormann","year":"2024","journal-title":"Transfus. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1111\/vox.13413","article-title":"Eye drops of human origin\u2014Current status and future needs: Report on the workshop organized by the ISBT Working Party for Cellular Therapies","volume":"118","author":"Gabriel","year":"2023","journal-title":"Vox Sang."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1111\/vox.12502","article-title":"Serum eye drops: A survey of international production methods","volume":"112","author":"Marks","year":"2017","journal-title":"Vox Sang."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1136\/bjo.2004.044347","article-title":"Autologous serum eye drops for ocular surface disorders","volume":"88","author":"Geerling","year":"2004","journal-title":"Br. J. Ophthalmol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.4103\/IJO.IJO_2756_22","article-title":"Autologous serum eye drops in dry eye disease: Preferred practice pattern guidelines","volume":"71","author":"Vazirani","year":"2023","journal-title":"Indian J. Ophthalmol."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Bernabei, F., Roda, M., Buzzi, M., Pellegrini, M., Giannaccare, G., and Versura, P. (2019). Blood-based treatments for severe dry eye disease: The need of a consensus. J. Clin. Med., 8.","DOI":"10.3390\/jcm8091478"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"96412","DOI":"10.5493\/wjem.v14.i4.96412","article-title":"Autologous blood in the management of ocular surface disorders","volume":"14","author":"Suleman","year":"2024","journal-title":"World J. Exp. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1111\/aos.14788","article-title":"Allogeneic and autologous serum eye drops: A pilot double-blind randomized crossover trial","volume":"99","author":"Verbakel","year":"2021","journal-title":"Acta Ophthalmol."},{"key":"ref_17","first-page":"e396","article-title":"Autologous versus allogeneic versus umbilical cord sera for the treatment of severe dry eye disease: A double-blind randomized clinical trial","volume":"100","author":"Lamas","year":"2022","journal-title":"Acta Ophthalmol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.jtos.2026.03.002","article-title":"Clinical evidence on allogeneic blood-derived eye drops in ocular surface and corneal diseases","volume":"40","author":"Ghalibafan","year":"2026","journal-title":"Ocul. Surf."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.ophtha.2019.08.018","article-title":"Autologous serum-based eye drops for treatment of ocular surface disease: A report by the American Academy of Ophthalmology","volume":"127","author":"Shtein","year":"2020","journal-title":"Ophthalmology"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1089\/jop.2012.0002","article-title":"Allogeneic serum eye drops for the treatment of dry eye patients with chronic graft-versus-host disease","volume":"28","author":"Na","year":"2012","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1111\/tme.13017","article-title":"Reactions to serum eye drops\u2014New Zealand experience and review of the literature","volume":"34","author":"Badami","year":"2024","journal-title":"Transfus. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"3347","DOI":"10.1007\/s40123-023-00827-5","article-title":"Allogeneic serum eye drops: A randomized clinical trial to evaluate the clinical effectiveness of two drop sizes","volume":"12","author":"Vermeulen","year":"2023","journal-title":"Ophthalmol. Ther."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.transci.2015.05.013","article-title":"A concise overview of advances in therapeutic efficacy of serum eye drops and their alternatives to treat dry eye syndrome: Verifying the narratives of clinical consistency beyond the periphery of international inconsistency on the methods of collection and application","volume":"53","author":"Seghatchian","year":"2015","journal-title":"Transfus. Apher. Sci."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"DES121","DOI":"10.1167\/iovs.17-23760","article-title":"Autologous serum and serum components","volume":"59","author":"Higuchi","year":"2018","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_25","first-page":"CD009327","article-title":"Autologous serum eye drops for dry eye","volume":"2","author":"Pan","year":"2017","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"3425","DOI":"10.1038\/s41433-021-01560-8","article-title":"Patient-reported outcome measures for a large cohort of serum eye drops recipients in the UK","volume":"35","author":"Lomas","year":"2021","journal-title":"Eye"},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Drew, V.J., Tseng, C.L., Seghatchian, J., and Burnouf, T. (2018). Reflections on dry eye syndrome treatment: Therapeutic role of blood products. Front. Med., 5.","DOI":"10.3389\/fmed.2018.00033"},{"key":"ref_28","first-page":"200","article-title":"Serum eye drops for the treatment of ocular surface diseases: A systematic review and meta-analysis","volume":"17","author":"Franchini","year":"2019","journal-title":"Blood Transfus."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/eye.2017.208","article-title":"The Royal College of Ophthalmologists guidelines on serum eye drops for the treatment of severe ocular surface disease: Executive summary","volume":"32","author":"Rauz","year":"2018","journal-title":"Eye"},{"key":"ref_30","first-page":"322","article-title":"Treatment of severe chronic ocular graft-versus-host disease using 100% autologous serum eye drops from a sealed manufacturing system: A retrospective cohort study","volume":"101","author":"Tahmaz","year":"2017","journal-title":"Br. J. Ophthalmol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1111\/vox.70142","article-title":"Including patient insights to improve the information materials provided to serum eye drop recipients","volume":"121","author":"Gemelli","year":"2026","journal-title":"Vox Sang."},{"key":"ref_32","unstructured":"European Directorate for the Quality of Medicines & HealthCare (EDQM) (2022). Guide to the Quality and Safety of Tissues and Cells for Human Application, Council of Europe. [5th ed.]."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1097\/ICO.0000000000000271","article-title":"Long-term use of autologous serum 50% eye drops for the treatment of dry eye disease","volume":"33","author":"Hussain","year":"2014","journal-title":"Cornea"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.transci.2015.11.011","article-title":"Sustained benefits of autologous serum eye drops on self-reported ocular symptoms and vision-related quality of life in Australian patients with dry eye and corneal epithelial defects","volume":"53","author":"Mondy","year":"2015","journal-title":"Transfus. Apher. Sci."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.jcjo.2017.09.007","article-title":"Serum drops for ocular surface disease: National survey of Canadian cornea specialists","volume":"53","author":"Marchand","year":"2018","journal-title":"Can. J. Ophthalmol."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/17\/6537\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T08:18:34Z","timestamp":1787645914000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/17\/6537"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,24]]},"references-count":35,"journal-issue":{"issue":"17","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["jcm15176537"],"URL":"https:\/\/doi.org\/10.3390\/jcm15176537","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,24]]}}}